Find Academic Supervisors

Barbara Given is a University Distinguished Professor in the College of Nursing at Michigan State University. Her research focuses on the interplay between formal healthcare systems and informal caregiver networks, particularly in oncology and geriatric populations. She has secured over 34 years of NIH funding, including grants from the National Cancer Institute, NIMH, and others. Dr. Given earned her Ph.D. at MSU, following a BSN and MSN from Ohio State University. Her work centers on caregiver burden, symptom management in chronic disease, and caregiver-patient communication. She developed the Caregiver Burden Instrument, widely used in research and clinical settings across multiple languages. Key research interests include: 1) caregiver stress and support systems, 2) symptom management in cancer patients, and 3) healthcare coordination challenges in aging populations. Her NIH-funded projects address adherence to oral chemotherapy, fall prevention in cancer survivors, and psychosocial outcomes post-treatment. Recent articles emphasize innovation in symptom tracking (e.g., text messaging for adherence), caregiver mental health barriers, and longitudinal symptom analysis. Awards/fellowships are not explicitly stated, though her sustained NIH support reflects significant recognition. Dr. Given advises on grants and mentors nurse researchers. She collaborates on interdisciplinary teams focused on palliative care, gerontology, and technology-based interventions. Her work bridges clinical practice and policy, advocating for integrated care models to reduce caregiver burden.

• Nursing
• Oncology Caregiver Support
• Symptom Management in Cancer Patients
• +3 more

Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.

• Mechanobiology
• Cancer biophysics
• Single-cell mechanics
• +6 more

Andrea E. Wahner Hendrickson, M.D., is an Associate Professor of Oncology and Assistant Professor of Pharmacology at the Mayo Clinic College of Medicine and Science. She holds primary appointments as a Consultant in the Division of Medical Oncology and serves as Interim Medical Director of the Early Phase Therapeutics Novel Agents Disease Team. Her research focuses on developing novel therapies for ovarian cancer, including PARP inhibitors and pharmacogenomics of platinum-taxane chemotherapy. She leads phase I clinical trials and investigates mechanisms of drug resistance and genomics of chemotherapy-induced neuropathy. Education: MD from University of Minnesota Medical School, postgraduate training in Hematology/Oncology at Mayo Clinic. Key Roles: Co-Principal Investigator in NRG trials, member of National Comprehensive Cancer Network Ovarian Cancer Guidelines panel. Her research interests include translational studies on ovarian cancer biology, optimizing therapeutic targets, and improving patient outcomes through personalized medicine. Over 5,000 patients have been studied in her pharmacogenomic work on peripheral neuropathy. She has received NIH-funded grants and awards, including the Paul Calabresi Career Development Award. Awards: Mayo Clinic Ovarian SPORE Award, Outstanding Medical Oncology Fellow Award. Dr. Hendrickson collaborates widely, engaging in international initiatives like the Mayo Clinic/Karolinska Institutet collaboration. Her work bridges clinical trials and laboratory research, aiming to streamline novel agent development from bench to bedside.

• Oncology
• Medical Oncology
• Cancer Therapeutics
• +8 more

Nikolai Podoltsev, MD, PhD, is an Associate Professor of Medicine (Hematology) at Yale University School of Medicine. He serves as the Associate Director of the Hematology/Oncology Fellowship Program and Clinical Director of Malignant Hematology within the Department of Internal Medicine. Dr. Podoltsev is also the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel. Dr. Podoltsev's research focuses on the management of patients with acute leukemias (including acute myeloid leukemias and acute lymphoblastic leukemia), myeloid neoplasms (such as myelodysplastic syndromes and myeloproliferative neoplasms), and bone marrow failure syndromes. His work spans clinical research, epidemiology, and patterns of care for patients with hematological malignancies. As a principal investigator, he leads multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies. Analysis of Dr. Podoltsev's recent publications (2024-2025) reveals a strong focus on therapeutic advancements in myeloid malignancies, particularly acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. His research spans drug development (including novel agents like imetelstat and luspatercept), combination therapies, treatment sequencing, and cost-effectiveness analyses. There is a clear emphasis on translating molecular understanding into clinical applications, with significant work on targeted therapies for specific genetic mutations. Yale Cancer Center Award for Clinical Excellence (2022) The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology (2021, 2017, 2011) As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev plays a pivotal role in hematology education for fellows, residents, and medical students. He is actively involved in multiple clinical trials through the Leukemia Clinical Research Team and the Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, which enables him to study epidemiology and patterns of care for hematological malignancies. Dr. Podoltsev is part of the Leukemia Disease Aligned Research Team (DART) at Yale Cancer Center, where he contributes to advancing treatment options for patients with blood cancers. His clinical expertise spans the full spectrum of malignant hematology with a particular focus on older adult patients.

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• +4 more

Brock C Christensen is a Professor at the Geisel School of Medicine , Dartmouth, affiliated with the Departments of Epidemiology , Community and Family Medicine , and Molecular and Systems Biology . His research integrates molecular biology, genomics, and bioinformatics with epidemiology to investigate epigenetic mechanisms in human health and disease. Harvard University, PhD (2008) University of Wisconsin - Madison, BS (2002) Dr. Christensen's work focuses on epigenetic susceptibility traits , environmental interactions, and translational applications in cancer diagnostics and treatment. His recent publications explore DNA methylation patterns in triple-negative breast cancer , head and neck cancer , and pediatric CNS tumors . He serves as course director for PEMM103: Introductory Applied Biostatistics with R and leads the Christensen Lab , which specializes in epigenomic profiling and computational biology.

• Epigenetics
• Cancer Biology
• Genomics
• +7 more

Yading Yuan, PhD is an Associate Professor of Radiation Oncology (Physics) at Columbia University Irving Medical Center and a member of the Data Science Institute. He holds a PhD in medical physics from the University of Chicago (2010) and completed clinical residency at Harvard Medical Physics Program (2013). His research focuses on AI-driven innovations in radiation oncology, including automated medical image analysis systems, federated learning frameworks for tumor segmentation, and data-driven approaches to personalized cancer treatment. He is certified by the American Board of Radiology and licensed in New York State. Education: PhD in Medical Physics (University of Chicago, 2010); Clinical Residency (Harvard Medical Physics Program, 2013). Research interests include: automated knowledge-based treatment planning, large-scale clinical AI systems, medical image reconstruction algorithms, and panomics integration for precision oncology. His work emphasizes translating data science advancements into clinical practice to improve patient outcomes. Key trends in his publications include federated learning for privacy-preserving medical AI, tumor segmentation in multi-modal imaging (PET/CT, MRI), and AI-driven prediction of treatment outcomes and recurrence risks. Recent work emphasizes decentralized learning architectures and cross-institutional collaboration systems. Scientific Awards: Distinguished Reviewers 2013 (selected by peer review committees) Advising/grants: No specific student names or grant details listed in provided text. His work is supported through institutional and collaborative research initiatives. Labs/teams: Active member of Columbia's Data Science Institute and Radiation Oncology department, contributing to interdisciplinary medical AI research groups.

• Artificial Intelligence in Radiation Oncology
• Medical Imaging Analysis
• Data Science Applications in Healthcare
• +3 more

Adam Caparco is the DiPietro Assistant Professor of Chemical Engineering at Northeastern University, with a 25% joint appointment in the Department of Chemistry and Chemical Biology. He leads the Caparco Research Group, focusing on agricultural and environmental biotechnology, enzyme immobilization, and protein assemblies. His work integrates plant virology, nanotechnology, and molecular engineering to address sustainability challenges in agriculture and environmental remediation. He is a member of the Institute for Plant-Human Interface and holds affiliations with Northeastern’s College of Engineering and School of Arts and Sciences. Education: B.S. in Chemical and Biomolecular Engineering from UCLA (2015), Ph.D. from Georgia Tech (2020) under Julie Champion and Andreas Bommarius, followed by a USDA NIFA Postdoctoral Fellowship at UC San Diego under Nicole Steinmetz. His research spans plant immunoengineering, biomanufacturing in plants, and protein-based nanomaterials for bioremediation. Research Interests Plant excretion pathways for pathogen defense and environmental remediation Design of immobilized enzymes for green chemical synthesis Plant virus nanoparticles for nucleic acid delivery and immunity modulation Multifunctional protein engineering for sustainable agriculture Recent articles highlight advancements in plant virus-based delivery systems, enzyme immobilization strategies, and nano-enabled precision agriculture. Awards include the USDA NIFA Postdoctoral Fellowship. Caparco advises graduate and undergraduate researchers, including Julia Hilgemberg Merlin (PhD ChE), Olha Bereziuk (PhD CCB), and Paul Carter (PhD ChE). He collaborates widely and seeks to expand interdisciplinary research in plant biotechnology. Labs/Teams: Caparco Research Group (EXP 420 lab, EXP 530B office) and the Institute for Plant-Human Interface.

• Agricultural Biotechnology
• Environmental Biotechnology
• Enzyme Immobilization
• +6 more

Seth Herzon is the Milton Harris '29 Ph.D. Professor of Chemistry at Yale University, with joint appointments in the Departments of Pharmacology and Therapeutic Radiology at the Yale School of Medicine. He is also a Member of the Yale Cancer Center and co-founder of Modifi Biosciences, which was acquired by Merck in Fall 2024. Herzon joined Yale in 2008 after completing his PhD at Harvard University and an NIH postdoctoral fellowship at the University of Illinois, Urbana-Champaign. Her research focuses on organic synthesis with an emphasis on the molecular mechanisms of action of DNA-damaging compounds, particularly anticancer and microbiome-derived natural products. His laboratory has made significant contributions to understanding colibactin, a gut microbiome metabolite that induces colorectal cancer, and has developed novel chemotherapies targeting DNA repair defects in tumors. His work spans synthetic chemistry, chemical biology, and translational medicine, with projects ranging from total synthesis of complex natural products to developing antibacterial agents. His recent publications reveal a strong trend toward microbiome-cancer interactions, particularly focusing on colibactin's role in carcinogenesis, alongside continued innovation in synthetic methodology and therapeutic development for drug-resistant cancers. His work bridges fundamental chemistry with clinical applications, particularly in cancer therapeutics. Among his numerous accolades are the NSF CAREER Award, Searle Scholar Award, Packard Fellowship, Sloan Fellowship, Arthur C. Cope Scholar Award, and the 2024 Yale Cancer Center Class of '61 Cancer Research Award. He served as Associate Editor for The Journal of Organic Chemistry from 2018-2023 and was a member of the United States Defense Science Study Group from 2018-2019. Herzon has mentored numerous PhD students and postdoctoral researchers who have gone on to successful careers in academia and industry. His laboratory at Yale continues to be at the forefront of chemical research with significant translational impact, particularly in cancer drug discovery. The lab maintains active collaborations with researchers across Yale, including in pharmacology, radiobiology, and cancer biology.

• Organic Synthesis
• Natural Products Chemistry
• DNA Damage and Repair
• +7 more

Joanne Wang is Professor of Pharmaceutics at the University of Washington School of Pharmacy and an Affiliate Investigator at the Fred Hutchinson Cancer Research Center. She holds additional appointments in multiple research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging Faculty, and Pharmaceutics Faculty. Her educational background includes: PhD in Pharmaceutical Chemistry, University of California, San Francisco (UCSF) MS in Biochemistry, University of Illinois at Chicago BS in Biochemistry, Peking University Dr. Wang's research focuses on solute carrier (SLC) and ATP-binding cassette (ABC) transporters that shuttle drugs, nutrients, neurotransmitters, and hormones across cell membranes. Her work encompasses elucidating mechanisms and clinical impact of transporters in nutrient and drug disposition and their potential as drug targets. Ongoing projects include identification and functional characterization of transporters in human placenta, mechanisms of drug secretion into breastmilk using PBPK modeling, and investigation of transporters in the disposition of meta-iodobenzylguanidine for cancer therapy. Analysis of her recent publications reveals a strong emphasis on transporter-mediated drug disposition in special populations, particularly during pregnancy and lactation, and at the blood-brain barrier. Her work spans from basic transporter characterization to clinical applications, with increasing focus on translational aspects including PBPK modeling and clinical implications of transporter polymorphisms. Dr. Wang is actively involved in mentoring, as evidenced by her lab accepting students. Her research has been supported by significant grants including a UC2 grant from NICHD for placental transporter research. Her multidisciplinary approach integrates in vitro models, in vitro-in vivo extrapolation, and PBPK modeling to address critical questions in drug disposition. She is affiliated with several research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging, and the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), reflecting the breadth and impact of her work across multiple domains of pharmacology and therapeutics.

• Blood-brain and blood-csf barriers
• Pharmacokinetics-Pharmacodynamics
• Pharmacology
• +5 more

Xiaodong Wang is a Professor at the Center for Integrative Chemical Biology and Drug Discovery within the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His research program focuses on developing innovative drug leads and candidates targeting novel protein kinases and other molecular targets identified by UNC faculty and external investigators. Dr. Wang's research interests center on structure- and ligand-based drug design approaches for developing therapeutic compounds, particularly kinase inhibitors targeting the TAM family (TYRO3, AXL, MERTK). His laboratory has successfully applied these methodologies to deliver compounds to clinical trials, including MerTK inhibitors and IDH1 inhibitors developed in collaboration with NCATS. Current research continues to focus on structure-based drug design for novel targets, with particular emphasis on cancer therapeutics and molecular imaging agents. Analysis of Dr. Wang's recent publications (2023-2025) reveals a strong focus on developing selective kinase inhibitors, particularly targeting the TAM receptor family (TYRO3, AXL, MERTK) for various cancer types including leukemia, Ewing sarcoma, and melanoma. His work spans multiple disciplines including medicinal chemistry, cancer biology, immunology, and molecular imaging, with recent publications appearing in high-impact journals such as Journal of Medicinal Chemistry, Nature Communications, and Leukemia. Dr. Wang maintains active collaborations across UNC-Chapel Hill and with external institutions, working with researchers in pharmacology, oncology, immunology, and structural biology. His laboratory develops both small molecule inhibitors and imaging agents, with several compounds progressing toward clinical applications. Contact information: xiaodonw@email.unc.edu | Wang Lab website

• Medicinal Chemistry
• Drug Discovery
• Kinase Inhibitors
• +3 more

Pia Vogel is a Professor in the Department of Biological Sciences at Southern Methodist University (SMU), where she leads research on nucleotide-binding proteins using Electron Spin Resonance spectroscopy and molecular modeling. Her work focuses on elucidating structural mechanisms in ATP synthase, multidrug resistance transporters, and calcium channels with biomedical applications in cancer therapy and neurodegenerative diseases. Education: Ph.D., University of Kaiserlautern Dr. Vogel's research program investigates three interconnected domains: the rotary mechanics of FoF1-ATP synthase (particularly the external stalk subunit b-dimer), the structural basis of multidrug resistance in P-glycoprotein and MRPs, and ATP-regulated calcium release via ryanodine receptors. Her laboratory employs site-specific spin labeling, ESR spectroscopy, and computational modeling to resolve protein dynamics and interactions at molecular resolution, contributing to understanding energy transduction in ATP synthase and mechanisms of drug resistance. Analysis of her 15 most recent publications (2020-2025) reveals a dominant focus on developing and characterizing P-glycoprotein and BCRP inhibitors to overcome chemotherapy resistance in cancer. These studies integrate computational screening, ATPase assays, and cell-based models to evaluate inhibitor efficacy, with emerging applications in Alzheimer's research through amyloid-β transport studies. The work demonstrates consistent methodological synergy between biophysical characterization and therapeutic development. Dr. Vogel maintains an active research group supported by sustained funding, evidenced by continuous publication output and laboratory infrastructure. Her team employs multidisciplinary approaches spanning biophysics, biochemistry, and computational biology to address fundamental questions in membrane protein function. Her laboratory facilities in DLSB 221 include specialized Electron Spin Resonance instrumentation and dual Linux computing clusters for molecular dynamics simulations. The research environment supports collaborative projects extending her work into cancer therapeutics and neurodegenerative disease mechanisms through partnerships with clinical and computational researchers.

• ATP Synthase
• Multidrug Resistance
• Ryanodine Receptor
• +5 more

Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.

• Tuberculosis
• Antibiotic Resistance
• Metabolomics
• +3 more

Hee Kwon Song, Ph.D. is an Associate Professor of Radiology at the University of Pennsylvania , affiliated with the Institute for Translational Medicine and Therapeutics and the Penn Center for Musculoskeletal Disorders . His expertise lies in MRI physics and MRI engineering , focusing on novel dynamic imaging strategies. Education: BS in Electrical Engineering, Northwestern University (1991) MS in Bioengineering, University of Pennsylvania (1994) PhD in Bioengineering, University of Pennsylvania (1999) Master of Law, University of Pennsylvania Carey Law School (2021) Dr. Song’s research specializes in dynamic contrast-enhanced MRI (DCE-MRI) using radial data acquisition and KWIC reconstruction for ultra-fast imaging. His work enables retrospective respiratory motion compensation and flexible resolution adjustments in tumor treatment monitoring ( lung, liver, breast, kidney, ovarian ). Applications extend to non-contrast MRA and tissue T1 mapping . Selected Publications demonstrate his focus on accelerated MRI , bone-selective imaging , and deep learning reconstruction , with collaborations spanning Medicine, Obstetrics and Gynecology, Neurology , and Radiation Oncology . Contact: heekwon.song@pennmedicine.upenn.edu

• MRI Physics
• Biomedical Engineering
• Medical Imaging
• +2 more

Martha R.C. Bhattacharya is an Associate Professor in the Department of Neuroscience at the University of Arizona, where she also serves as Faculty Director of the Vertically Integrated Projects (VIP) program. She holds a Ph.D. from UCSF, focusing on mechanotransduction under Dr. David Julius, and completed postdoctoral training at Washington University in St. Louis with Dr. Aaron DiAntonio, studying axon degeneration mechanisms. She joined the University of Arizona in 2017 and received tenure in 2023. Her research investigates molecular mechanisms of axon degeneration using Drosophila and mouse models, with a focus on neurodegenerative diseases such as ALS and Alzheimer’s. Key discoveries include identifying MORN4 and TMEM184B as mediators of axon degeneration. Her work also explores TMEM184B’s role in itch sensation and synaptic dysfunction. Dr. Bhattacharya has received prestigious awards, including the NSF CAREER Award and the Five Star Faculty Award for Teaching Excellence. She leads a dynamic lab mentoring numerous students and has secured NIH R01 and R21 grants. Her educational initiatives, such as the Brain Communication Networks CURE course, emphasize undergraduate research training. Her lab collaborates widely, including with Dr. Sean Sweeney on Drosophila models, and has contributed to translational studies on TMEM184B-associated diseases. Future work includes exploring human stem cell models and advancing therapies for neurodegenerative conditions.

• Axon Degeneration
• Neurodegenerative Diseases
• Molecular Mechanisms
• +3 more

Horst A. von Recum, PhD, is the Executive Vice Chair of the Case School of Engineering and a Professor in the Department of Biomedical Engineering at Case Western Reserve University. He is also a member of the Cancer Imaging Program at the Case Comprehensive Cancer Center. His research focuses on developing novel platforms for molecular and cellular delivery, including affinity-based systems for controlled drug release and directed stem cell differentiation. Key applications include HIV therapies, wound healing, ocular disease treatments, and tissue engineering. His work emphasizes improving drug delivery precision through molecular interactions and enhancing stem cell viability for therapeutic use. Dr. von Recum’s research interests span drug delivery systems, biomaterials science, and regenerative medicine. His lab explores cyclodextrin polymers for sustained antibiotic release, affinity-driven drug refilling mechanisms, and engineering biocompatible materials to combat implant-related infections. Recently, his team has investigated microbiome interactions with neural implants and developed polymer-based solutions for localized chemotherapy. Notable contributions include advancements in PMMA bone cement composites for drug refillable depots, cyclodextrin hydrogels for controlled release, and affinity-based systems for anti-fibrotic treatments. His work bridges materials science with clinical applications, addressing challenges in orthopedic infections, neural interfaces, and cardiovascular regeneration. Scientific achievements include over 100 peer-reviewed publications. Research funding has supported projects on antimicrobial coatings, drug delivery mechanics, and stem cell differentiation. Dr. von Recum collaborates across disciplines to translate biomaterial innovations into clinical solutions.

• Drug Delivery Systems
• Biomedical Engineering
• Stem Cell Differentiation
• +4 more